share_log

6-K: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe Rsv Disease in Japan

6-K: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe Rsv Disease in Japan

6-K:Arexvy在日本的获批范围扩大至50-59岁患有严重呼吸道合胞病毒疾病风险较高的成年人
美股SEC公告 ·  11/22 22:25
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息